[1]
|
Cakir, M., Polat, A., Tekin, S., Vardi, N., Taslidere, E., Rumeysa Duran, Z., et al. (2015) The Effect of Dexmedetomidine against Oxidative and Tubular Damage Induced by Renal Ischemia Reperfusion in Rats. Renal Failure, 37, 704-708. https://doi.org/10.3109/0886022x.2015.1011550
|
[2]
|
Schmitz, J. and Holzgrabe, U. (2011) Die Entwicklung Selektiver α2-Rezeptor-Agonisten. Pharmazie in unserer Zeit, 40, 496-502. https://doi.org/10.1002/pauz.201100446
|
[3]
|
杨峰, 林成新. 右美托咪定心血管效应的机制[J]. 临床麻醉学杂志, 2021, 37(9): 999-1002.
|
[4]
|
杨逸成, 陈贝儿, 叶凯雁, 等. 右美托咪定的心脏保护机制及其临床应用价值[J]. 中国医学科学院学报, 2022, 44(1): 130-135.
|
[5]
|
Roekaerts, P.M., Prinzen, F.W. and De Lange, S. (1996) Beneficial Effects of Dexmedetomidine on Ischaemic Myocardium of Anaesthetized Dogs. British Journal of Anaesthesia, 77, 427-429. https://doi.org/10.1093/bja/77.3.427
|
[6]
|
万军. 右美托咪定对冠心病患者围手术期心率和血压的影响[J]. 中国医学创新, 2014, 11(26): 47-49.
|
[7]
|
张海媛. 右美托咪定不同给药方式用于妇科腹腔镜手术的临床麻醉效果比较[J]. 中国实用医药, 2020, 15(3): 141-142.
|
[8]
|
Kunisawa, T., Nagata, O., Nagashima, M., Mitamura, S., Ueno, M., Suzuki, A., et al. (2009) Dexmedetomidine Suppresses the Decrease in Blood Pressure during Anesthetic Induction and Blunts the Cardiovascular Response to Tracheal Intubation. Journal of Clinical Anesthesia, 21, 194-199. https://doi.org/10.1016/j.jclinane.2008.08.015
|
[9]
|
Chrysostomou, C., Beerman, L., Shiderly, D., Berry, D., Morell, V.O. and Munoz, R. (2008) Dexmedetomidine: A Novel Drug for the Treatment of Atrial and Junctional Tachyarrhythmias during the Perioperative Period for Congenital Cardiac Surgery: A Preliminary Study. Anesthesia & Analgesia, 107, 1514-1522. https://doi.org/10.1213/ane.0b013e318186499c
|
[10]
|
Chrysostomou, C., Morell, V.O., Wearden, P., Sanchez-de-Toledo, J., Jooste, E.H. and Beerman, L. (2012) Dexmedetomidine: Therapeutic Use for the Termination of Reentrant Supraventricular Tachycardia. Congenital Heart Disease, 8, 48-56. https://doi.org/10.1111/j.1747-0803.2012.00669.x
|
[11]
|
杨毅峰, 叶楠, 王琳, 等. 右美托咪定抗缺血再灌注损伤的信号通路[J]. 中国组织工程研究, 2024, 28(9): 1464-1469.
|
[12]
|
Ibacache, M., Sanchez, G., Pedrozo, Z., Galvez, F., Humeres, C., Echevarria, G., et al. (2012) Dexmedetomidine Preconditioning Activates Pro-Survival Kinases and Attenuates Regional Ischemia/Reperfusion Injury in Rat Heart. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, 1822, 537-545. https://doi.org/10.1016/j.bbadis.2011.12.013
|
[13]
|
Rossello, X. and Yellon, D.M. (2017) The RISK Pathway and Beyond. Basic Research in Cardiology, 113, Article 2. https://doi.org/10.1007/s00395-017-0662-x
|
[14]
|
Chang, J., Jin, M. and Liu, J. (2020) Dexmedetomidine Pretreatment Protects the Heart Against Apoptosis in Ischemia/Reperfusion Injury in Diabetic Rats by Activating PI3K/Akt Signaling in Vivo and in Vitro. Biomedicine & Pharmacotherapy, 127, Article ID: 110188. https://doi.org/10.1016/j.biopha.2020.110188
|
[15]
|
Zhang, J., Jiang, H., Liu, D.H., et al. (2019) Effects of Dexmedetomidine on Myocardial Ischemia-Reperfusion Injury through PI3K-Akt-mTOR Signaling Pathway. European Review for Medical and Pharmacological Sciences, 23, 6736-6743.
|
[16]
|
Song, J., Du, J., Tan, X., Wu, Z., Yuan, J. and Cong, B. (2021) Dexmedetomidine Protects the Heart against Ischemia Reperfusion Injury via Regulation of the Bradykinin Receptors. European Journal of Pharmacology, 911, Article ID: 174493. https://doi.org/10.1016/j.ejphar.2021.174493
|
[17]
|
Zhang, J., Peng, K., Zhang, J., Meng, X. and Ji, F. (2017) Dexmedetomidine Preconditioning May Attenuate Myocardial Ischemia/Reperfusion Injury by Down-Regulating the HMGB1-TLR4-MyD88-NF-кB Signaling Pathway. PLOS ONE, 12, e0172006. https://doi.org/10.1371/journal.pone.0172006
|
[18]
|
Zhang, J., Xia, F., Zhao, H., Peng, K., Liu, H., Meng, X., et al. (2019) Dexmedetomidine-Induced Cardioprotection Is Mediated by Inhibition of High Mobility Group Box-1 and the Cholinergic Anti-Inflammatory Pathway in Myocardial Ischemia-Reperfusion Injury. PLOS ONE, 14, e0218726. https://doi.org/10.1371/journal.pone.0218726
|
[19]
|
Hu, X., li, J., Fu, M., Zhao, X. and Wang, W. (2021) The JAK/STAT Signaling Pathway: From Bench to Clinic. Signal Transduction and Targeted Therapy, 6, Article No. 402. https://doi.org/10.1038/s41392-021-00791-1
|
[20]
|
Chen, Z., Hong, Y., Wen, S., Zhan, Y. and Huang, W. (2023) Dexmedetomidine Pretreatment Protects against Myocardial Ischemia/Reperfusion Injury by Activating STAT3 Signaling. Anesthesia & Analgesia, 137, 426-439. https://doi.org/10.1213/ane.0000000000006487
|
[21]
|
张晓秀, 吴海鹰, 王艳雪, 等. 右美托咪定激活Nrf2-ARE信号通路对创伤性脑损伤的抗氧化作用[J]. 中华重症医学电子杂志(网络版), 2018, 4(2): 176-181.
|
[22]
|
Li, H., Wang, T., Wu, L., Xue, F., Zhang, G. and Yan, T. (2022) Role of Keap1-Nrf2/Are Signal Transduction Pathway in Protection of Dexmedetomidine Preconditioning against Myocardial Ischemia/Reperfusion Injury. Bioscience Reports, 42, BSR20221306. https://doi.org/10.1042/bsr20221306
|
[23]
|
Han, H., Dai, D., Hu, J., Zhu, J., Lu, L., Tao, G., et al. (2019) Dexmedetomidine Improves Cardiac Function and Protects against Maladaptive Remodeling Following Myocardial Infarction. Molecular Medicine Reports, 20, 5183-5189. https://doi.org/10.3892/mmr.2019.10774.
|
[24]
|
Wu, Z., Davis, J.R.J. and Zhu, Y. (2020) Dexmedetomidine Protects against Myocardial Ischemia/Reperfusion Injury by Ameliorating Oxidative Stress and Cell Apoptosis through the Trx1-Dependent Akt Pathway. BioMed Research International, 2020, Article ID: 8979270. https://doi.org/10.1155/2020/8979270
|
[25]
|
Riquelme, J.A., Westermeier, F., Hall, A.R., Vicencio, J.M., Pedrozo, Z., Ibacache, M., et al. (2016) Dexmedetomidine Protects the Heart against Ischemia-Reperfusion Injury by an Endothelial eNOS/NO Dependent Mechanism. Pharmacological Research, 103, 318-327. https://doi.org/10.1016/j.phrs.2015.11.004
|
[26]
|
Yoshikawa, Y., Hirata, N., Kawaguchi, R., Tokinaga, Y. and Yamakage, M. (2018) Dexmedetomidine Maintains Its Direct Cardioprotective Effect against Ischemia/Reperfusion Injury in Hypertensive Hypertrophied Myocardium. Anesthesia & Analgesia, 126, 443-452. https://doi.org/10.1213/ane.0000000000002452
|
[27]
|
Wang, M., Pan, W., Xu, Y., Zhang, J., Wan, J. and Jiang, H. (2022) Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases. Journal of Inflammation Research, 15, 3083-3094. https://doi.org/10.2147/jir.s350109
|
[28]
|
丁允莹, 嵇富海, 彭科. 右美托咪定的器官保护作用及其机制概述[J]. 解放军医学杂志, 2023, 48(11): 1267-1275.
|
[29]
|
Ramkiran, S. (2015) BIS Targeted Propofol Sparing Effects of Dexmedetomidine versus Ketamine in Outpatient ERCP: A Prospective Randomised Controlled Trial. Journal of Clinical and Diagnostic Research, 9, UC07-UC12. https://doi.org/10.7860/jcdr/2015/12435.5991 9(5):Uc07-12.
|
[30]
|
Kimura, M., Ichimura, S., Sasaki, K., Masuya, H., Suzuki, T., Wakana, S., et al. (2015) Endoplasmic Reticulum Stress-Mediated Apoptosis Contributes to a Skeletal Dysplasia Resembling Platyspondylic Lethal Skeletal Dysplasia, Torrance Type, in a Novel Col2a1 Mutant Mouse Line. Biochemical and Biophysical Research Communications, 468, 86-91. https://doi.org/10.1016/j.bbrc.2015.10.160
|
[31]
|
Yang, Y., Wang, H., Song, N., Jiang, Y., Zhang, J., Meng, X., et al. (2021) Dexmedetomidine Attenuates Ischemia/Reperfusion-Induced Myocardial Inflammation and Apoptosis through Inhibiting Endoplasmic Reticulum Stress Signaling. Journal of Inflammation Research, 14, 1217-1233. https://doi.org/10.2147/jir.s292263
|
[32]
|
Říha, H., Kotulák, T., Březina, A., Hess, L., Kramář, P., Szárszoi, O., et al. (2012) Comparison of the Effects of Ketamine-Dexmedetomidine and Sevoflurane-Sufentanil Anesthesia on Cardiac Biomarkers after Cardiac Surgery: An Observational Study. Physiological Research, 61, 63-72. https://doi.org/10.33549/physiolres.932224
|
[33]
|
Wang, D., Lin, Q., Du, M., Zheng, G., Xu, W., Zhang, H., et al. (2020) Protective Effect of Dexmedetomidine on Perioperative Myocardial Injury in Patients With Stanford Type-a Aortic Dissection. Revista da Associação Médica Brasileira, 66, 1638-1644. https://doi.org/10.1590/1806-9282.66.12.1638
|
[34]
|
Wang, L., Wang, S., Xing, Z., Li, F., Teng, J. and Jia, T. (2020) Application of Dexmedetomidine in Cardiopulmonary Bypass Prefilling. Dose-Response, 18. https://doi.org/10.1177/1559325820939764
|
[35]
|
Elgebaly, A., Fathy, S., Sallam, A. and Elbarbary, Y. (2020) Cardioprotective Effects of Propofol-Dexmedetomidine in Open-Heart Surgery: A Prospective Double-Blind Study. Annals of Cardiac Anaesthesia, 23, 134-141. https://doi.org/10.4103/aca.aca_168_18
|
[36]
|
Ueki, M., Kawasaki, T., Habe, K., Hamada, K., Kawasaki, C. and Sata, T. (2014) The Effects of Dexmedetomidine on Inflammatory Mediators after Cardiopulmonary Bypass. Anaesthesia, 69, 693-700. https://doi.org/10.1111/anae.12636
|
[37]
|
Torregroza, C., Feige, K., Schneider, L., Bunte, S., Stroethoff, M., Heinen, A., et al. (2020) Influence of Hyperglycemia on Dexmedetomidine-Induced Cardioprotection in the Isolated Perfused Rat Heart. Journal of Clinical Medicine, 9, Article 1445. https://doi.org/10.3390/jcm9051445
|